Compare AU
Compare ETPMPD vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are ETPMPD and DRUG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
ETPMPD | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 12 | 63 |
Median incremental investment | $700.00 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,831.05 | $1,875.72 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
ETPMPD | DRUG | |
|---|---|---|
Strategy | ETPMPD.AX was created on 2009-01-02 by MUFG. The fund's investment portfolio concentrates primarily on palladium commodities. ETFS Physical Palladium (ASX Code: ETPMPD.AX) is designed to offer investors a simple, cost efficient and secure way to access physical palladium by providing a return equivalent to the movements in the palladium spot price less the applicable management fee. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Physical Palladium (100 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 0.49 % | 0.57 % |
Key Summary
ETPMPD | DRUG | |
|---|---|---|
Issuer | MUFG | BetaShares |
Tracking index | LBMA Palladium Spot Price AUD | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.49 % | 0.57 % |
Price | $140.85 | $8.12 |
Size | $10.419 million | $191.120 million |
10Y return | 62.79 % | N/A |
Annual dividend/ distribution yield (5Y) | - % | 1.90 % |
Market | ASX | ASX |
First listed date | 30/01/2009 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
ETPMPD | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 12 | 63 |
Median incremental investment | $700.00 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,831.05 | $1,875.72 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
ETPMPD | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
ETPMPD | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |